

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

#### Premium Sponsors



sanofi



Johnson & Johnson  
Innovative Medicine

#### Standard Sponsors



UK  
Myeloma  
Society

## UK Myeloma Society Spring Day Optimising Outcomes in Myeloma

Wednesday 19<sup>th</sup> March 2025

Hybrid Event from the Cavendish Conference Centre  
22 Duchess Mews, London W1G 9DT

Register to attend in person or watch a live stream

**Joint Chairs:** **Dr Mamta Garg** (University Hospitals of Leicester)  
**Dr Jennifer Travers** (Beatson West of Scotland Cancer Centre)

09.00 *Registration, coffee & exhibition*

09.30 UK practice updates

UK trials updates

### Minimal Residual Disease (MRD) Testing in Multiple Myeloma

10.00 Mass spectrometry

**Dr Hannah Giles**  
University Hospitals Birmingham

10.15 Flow cytometry

**Dr Roger Owen**  
Leeds Teaching Hospitals

10.30 Next generation sequencing

**Dr Angela Hamblin**  
Oxford University Hospitals

10.45 Is there a role for MRD in the UK?

**Dr Karthik Ramasamy**  
Oxford University Hospitals

11.05 Audience vote and panel discussion

11.20 *Coffee break & exhibition*

### IMS / ASH Bursary Winners

11.50 Progression from smouldering myeloma to myeloma is accompanied by an increase in CD56 bright bone marrow resident NK cells with reduced NK cell cytotoxic capacity

**Dr Elise Rees**  
UCL Cancer Institute

12.00 Tolerability and clinical activity of novel first-in-class oral agent, inobrodib (CCS1477), in combination with polidomide and dexamethasone in relapsed/refractory multiple myeloma

**Dr Emma Searle**  
The Christie Hospital, Manchester

12.10 Automated body composition analyses reveal significant associations with mortality in myeloma patients following immunotherapy with bispecific antibodies

**Dr Charles Agbuduwe**  
Imperial College London

12.20 *Lunch, networking & exhibition*

### Michael Morley Lecture

13.20 Results from the Iceland screens, treats or prevents multiple myeloma (iStopMM) study

**Professor Sigurður Kristinnsson**  
University of Iceland

14.20 *Coffee break*

### Goals of Myeloma Therapy

14.50 Case presentations and voting

15.00 Aims of induction therapy in fit myeloma patients

**Professor Kwee Yong**  
University College London

15.25 Aims of induction therapy in frail myeloma patients

**Dr Charlotte Pawlyn**  
Institute of Cancer Research

15.50 Aims of therapy in relapsed and refractory myeloma

**Dr Matthew Jenner**  
University Hospital Southampton

16.15 Case presentations and panel discussion

16.30 *Close*

### Registration:

Standard Fee (until 4 March)  
£75 (£50 for Scientists, Nurses & Pharmacists)

Late Fee (from 5 March)  
£125 (£85 for Scientists, Nurses & Pharmacists)

**Registration now open at [www.collaborativeconferences.co.uk/ukmsociety](http://www.collaborativeconferences.co.uk/ukmsociety)**

*Online registration for this meeting is for healthcare professionals only  
Please indicate if you wish to attend in person or watch the live stream while completing the registration form*

**Enquiries: Please contact Alex - [alex@collaborativeconferences.co.uk](mailto:alex@collaborativeconferences.co.uk)**

The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials

### Premium Sponsors



### Standard Sponsors



*All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.*